Summary
A plasminogen activating factor has been isolated and partially characterized in low salt cytosol from human breast cancer. The activity can be precipitated with 40% saturated ammonium sulphate as a high molecular weight aggregate (MW approximately 500,000). The aggregate dissociates in high salt buffer, and chromatography on Sephacryl S-300 or sucrose density gradient centrifugation in 400 mM KCl buffer gives a molecular weight of approximately 55,000. The substance binds with high affinity to lysine-Sepharose and can be eluted from lysine-Sepharose columns with 1.5M NaCl. Affinity chromatography on lysine-Sepharose separates the activator from plasminogen and from inhibitors of plasminogen activation. The activator is irreversibly inhibited by 2 mM DFP (di-isopropyl-fluorophosphate).
The plasminogen activating activity (PAA) measured in ammonium sulphate precipitates or affinity column eluates from separate cytosols shows a significant correlation with concentrations of estradiol and progesterone receptors in the corresponding cytosols. The presence of PAA seems to be strictly dependent on the simultaneous presence of progesterone receptor in the tumor, and discriminates sharply between PgR positive and negative tumors, irrespective of estrogen receptor status.
Similar content being viewed by others
References
Quigley J: Proteolytic enzymes in normal and malignant cells.In RO Hynes (ed). Surfaces of Normal and Malignant Cells. J Wiley & Sons, Chichester, UK, 1979, pp 247–285.
Christman JK, Silverstein SC, Acs G: Plasminogen activators.In AJ Barrett (ed). Proteinases in Mammalian Cells and Tissues. North Holland, Amsterdam, 1979, pp 91–149.
McCabe RP, Evans CH: Plasminogen activator, fibronectin, lymphotoxin sensitivity and natural skin reactivity. Relationships to guinea pig cell tumorigenicity. J Natl Cancer Inst 68: 329–335, 1982.
Goldfarb RH, Quigley JP: Synergistic effect of tumor virus transformation and tumor promoter treatment on the production of plasminogen activator by chick embryo fibroblasts. Cancer Res 38: 4601–4609, 1978.
Wigler M, Weinstein IB: Tumor promoter induces plasminogen activator. Nature 259: 232–233, 1976.
Hozumi M, Ogawa M, Sugimura T, Takeuchi T, Umezawa H: The inhibition of tumorigenesis in mouse skin by leupeptin, a protease inhibitor from Actinomycetes. Cancer Res 32: 1725–1729, 1972.
Troll W, Karlsen A, Janoff A: Tumorigenesis in mouse skin: Inhibition by synthetic inhibitors of proteases. Science 169: 1211–1213, 1970.
Kennedy AR, Weichelbaum RR: Effects of 17-beta estradiol on radiation transformation in vitro. Inhibition of effects by protease inhibitors. Carcinogenesis 2: 67–69, 1981.
Evers JL, Jashbhai P, Madeja JM, Schneider SL, Hobika GH, Camiolo SM, Markus G: Plasminogen activator activity and composition in human breast cancer. Cancer Res 42: 219–226, 1982.
Nagy B, Ban J, Brdar B: Fibrinolysis associated with human neoplasia: Production of plasminogen activators by human tumors. Int J Cancer 19: 614–620, 1977.
Ossowski L, Niegel D, Reich E: Mammary plasminogen activator: Correlation with evolution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 16: 929–940, 1979.
Mark TW, Rutledge G, Sutherland DJ: Androgen dependent fibrinolytic activity in mouse mammary carcinoma (Shionogi SC 115) cells in vitro. Cell 7: 223–226, 1976.
Butler WB, Kirkland WL, Jorgensen TL: Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7). Biochem Biophys Res Commun 90: 1328–1334, 1979.
Wilson EL, Dutlow C, Dowdle EB: Characterization of a new hormonally responsive human breast carcinoma cell line (Abstract).In Growth of Cells in Hormonally Defined Media, September 1–4, 1981, Cold Spring Harbour, New York, p 101.
Sherman MS, Tuazon FB, Miller LK: Estrogen receptor cleavage and plasminogen activation by enzymes in human breast cancer cytosol. Endocrinology 106: 1715–1727, 1980.
Sutherland DJ: Plasminogen activating activity: Association with steroid binding by cytosols of human breast cancer. J Natl Cancer Inst 64: 3–7, 1980.
Thorsen T: Association of plasminogen activator activity and steroid receptors in human breast cancer. J Steroid Biochem 18: 129–132, 1982.
McGuire WL, Horwitz KG, Chamness GC, Zava DT: A physiological role for estrogen and progesterone receptors in breast cancer. J Steroid Biochem 7: 875–882, 1976.
Overwien B, Neumann C, Sorge C: Detection of plasminogen activator in macrophage culture supernatants by a photometric assay. Hoppe-Seylers Z Physiol Chem 361: 1251–1255, 1980.
Radcliffe R, Heinze T: Isolation of plasminogen activator from human plasma by chromatography on lysine-Sepharose. Arch Biochem Biophys 189: 185–194, 1978.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thorsen, T. Some properties of a plasminogen activating factor in human breast cancer cytosol and its relation to steroid receptors. Breast Cancer Res Tr 2, 385–390 (1982). https://doi.org/10.1007/BF01805880
Issue Date:
DOI: https://doi.org/10.1007/BF01805880